UNDERSTANDING BLOOD TESTS

Similar documents
SGK 2016 Session: Postgraduate Course in Heart Failure Lausanne, 15. June 2016 Heart Failure Guidelines 2016

Disclosures. Advances in Chronic Heart Failure Management 6/12/2017. Van N Selby, MD UCSF Advanced Heart Failure Program June 19, 2017

Chronic Kidney Disease (CKD) and egfr: Decision and Dilemma. Dr Bhavna K Pandya Consultant Nephrologist University Hospital Aintree

8:30-10:30 WS #4: Cardiology :00-13:00 WS #11: Cardiology 101 (Repeated)

Disclosures. Overview. Goal statement. Advances in Chronic Heart Failure Management 5/22/17

Treating HF Patients with ARNI s Why, When and How?

Trial to Reduce. Aranesp* Therapy. Cardiovascular Events with

Patient details GP details Specialist details Name GP Name Dr Specialist Name Dr R. Horton

From PARADIGM-HF to Clinical Practice. Waleed AlHabeeb, MD, MHA Associate Professor of Medicine President of the Saudi Heart Failure Group

Diagnosis and management of Chronic Heart Failure in 2018: What does NICE say? PCCS Meeting Issues and Answers Conference Nottingham

INIBITORI NEPRILISINA

Iron Deficiency: New Therapeutic Target in Heart Failure. Stefan D. Anker, MD PhD

Cardiovascular Pharmacotherapy

Outline. Classification by LVEF Conventional Therapy New Therapies. Ivabradine Sacubitril/valsartan

Heart Failure Update. Chim Lang

Biomarker-guided HF: What have we learned (so far)?

HeFSSA Practitioners Program 2017 Theme The Patient Journey: Feel Good and Live Long. Case Study 2

Drugs acting on the reninangiotensin-aldosterone

Chronic heart failure: management of chronic heart failure in adults in primary and secondary care (partial update)

Management of chronic heart failure: pharmacology. Giuseppe M.C. Rosano, MD, PhD, FHFA

ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure

Authorised: JSWoodford, Lead of Speciality. Biochemistry Reference Intervals, October Page 1 of 5

10 Essential Blood Tests PART 1

Heart Failure Update. Bibiana Cujec MD May 2015

2016 ESC Guidelines for the Diagnosis and treatment of Acute & Chronic Heart Failure

HF-Preserved Ejection Fraction

Effect of ferric carboxymaltose on functional capacity in patients with heart failure and iron deficiency (CONFIRM-HF)

Akash Ghai MD, FACC February 27, No Disclosures

ESC Guidelines for the Diagnosis and Treatment of Chronic Heart Failure

Supplementary Online Content

Anaemia in Chronic Heart Failure

The CCS Heart Failure Companion: Bridging Guidelines to your Practice

ANGIOTENSIN RECEPTOR-NEPRILYSIN INHIBITORS IN HEART FAILURE FROM CHD

Cardiorenal and Renocardiac Syndrome

Overview & Update on the Utilization of the Natriuretic Peptides in Heart Failure

Management of chronic heart failure: update J. Parissis Attikon University Hospital

Office Management of Reduced GFR Practical advice for the management of CKD

Frimley Health Area Prescribing Committee

Biomarkers for optimal management of heart failure. Cardiorenal syndrome. Veli-Pekka Harjola Helsinki University Central Hospital Helsinki, Finland

RED CELL DISTRIBUTION WIDTH

CKD & HT. Anne-Marie Angus

Congestive Heart Failure: Outpatient Management

The Use of Tests in Clinical Biochemistry Interpreting Blood Results. Rowland Reece Principal Clinical Biochemist St. Vincent s University Hospital

Tiny Jaarsma Linköping University No conflict of interest

Heart Failure Hospitalisation: An opportunity to reset chronic therapy with Entresto?

Dr Emma Copsey Consultant Cardiologist Glenfield Hospital 28 th September 2017

New NICE Heart Failure Guidelines What do they mean for primary and secondary care, and patients?

Anemia and Iron Deficiency: What Every Cardiologist Needs to Know

The Triple Threat. Cardiac Care in the NT Annual Workshop 2017 is proudly supported by:

Natriuretic Peptide Guided Therapy for Heart Failure

Heart Failure. Optimising treatment and balancing co-morbidity in the community. Andrew Ludman Cardiologist

Doppler ultrasound, see Ultrasonography. Magnetic resonance imaging (MRI), kidney oxygenation assessment 75

Heart failure in diabetes: consequences for diagnosis and therapy

Nora Goldschlager, M.D. SFGH Division of Cardiology UCSF

DIABETES AND LABORATORY TESTS. Author: Josephine Davis

Heart failure and co-morbidities

Sacubitril/valsartan: A New Management Strategy for the Treatment of Heart Failure. Elizabeth Pogge, PharmD, MPH, BCPS, FASCP

Nephrology. 3 rd Year Revision Session 06/05/17 Cathal Hannan

Aldosterone Antagonism in Heart Failure: Now for all Patients?

Systolic Dysfunction Clinical/Hemodynamic Guide for Management; New Medical and Interventional Therapeutic Challenges

Case Presentation. This presentation is the intellectual property of the author. Contact them for permission to reprint and/or distribute.

DECLARATION OF CONFLICT OF INTEREST

ST2 in Heart Failure. ST2 as a Cardiovascular Biomarker. Competitive Model of ST2/IL-33 Signaling. ST2 and IL-33: Cardioprotective

Heart Failure A Disease for the Internist?

Irish Practice Nurses Association Annual Conference Tullamore Court Hotel OCTOBER 6 th 2012

Iron deficiency in heart failure

Biomarkers in the Age of Sacubitril/Valsa rten: Has the PARADIGM Changed

NICE Chronic Heart Failure Guidelines in Adults 2018

Heart Failure: Current Management Strategies

SUPPLEMENTARY DATA. Supplementary Table 1. Baseline Patient Characteristics

Analyte Specimen Demographic Reference Range Units

Type 2 Diabetes. Stopping Smoking. Consider referral to smoking cessation. Consider referring for weight management advice.

Angiotensin Converting Enzyme inhibitor (ACEi) / Angiotensin Receptor Blocker (ARB) To STOP OR Not in Advanced Renal Disease

SydPath Reference Intervals for Clinical Trials (Contract Pathology Unit) Unauthorised Copy

The Patient Journey through Heart Failure Primary Care Handout

Acute Kidney Injury in the ED

HFpEF, Mito or Realidad?

Interpreting Blood Tests Part 1. Dr Andrew Smith

Hyponatraemia- Principles, Investigation and Management. Sirazum Choudhury Biochemistry

Pravin Manga Division of Cardiology Department of Medicine University of Witwatersrand

Heart Failure. A Marvellous Story with More to Come. Prof Ken McDonald National Clinical Lead for Heart Failure

Update on pharmacological treatment of heart failure. Aldo Pietro Maggioni, MD, FESC ANMCO Research Center Firenze, Italy

Sacubitril/Valsartan in HFrEF for All Protagonist View George Honos MD FRCPC FCCS FACC

Heart Failure. GP Update Refresher 18 th January 2018

Cardiorenal Syndrome

2017 CCS HF Guidelines Medical Therapy for HFrEF When What Order and How Much?

ARNI (Angiotensin Receptor blocker / Neprilysin Inhibitors [Sacubutril/Valsartan]) Heart Failure Medication Initiation and Titration

Management of Heart Failure from diagnosis to the grave. Richard Lawrance Consultant Cardiologist - WMH

Supplementary Appendix

2016 ESC Heart Failure Guidelines: what is new? Piotr Ponikowski Wroclaw, Poland

Heart-failure or Kidney Failure?

Updates in Heart Failure (HF) 2016: ACC / AHA and ESC

ESCBM meeting 2018, Prague Utility of Cardiac Biomarkers in Clinical Heart Failure Care. Md. Shahidul Islam, M.D., Ph.D

GP refresher course Anaemia. Peter MacCallum Consultant Haematologist Barts Health NHS Trust London January 2018

Comorbidities in Heart Failure: Iron Deficiency. Ammar Chaudhary, MBChB, FRCPC King Faisal Specialist Hospital and Research Centre - Jeddah

The clinical value of natriuretic peptide testing in heart failure

Heart Failure Clinician Guide JANUARY 2016

Highlight Session Heart failure and cardiomyopathies Michel KOMAJDA Paris France

Iron metabolism anemia and beyond. Jacek Lange Perm, 8 October 2016

A patient with decompensated HF

Transcription:

UNDERSTANDING BLOOD TESTS Parminder Chaggar Cardiology SpR Northern General Hospital Sheffield Conflict of Interest: Nil

OVERVIEW Monitoring drug titration Markers of risk Iron deficiency Thyroid disease Tips and tricks

MONITORING DRUG TITRATION

Commencing ACEi / ARB Caution if Cr >220 umol/l or K + >5 mmol/l Discontinue other drugs (NSAID, diuretics, MRA) before ACEi / ARB Acceptable increases 50% increase in Cr or Cr up to 266 umol/l K+ up to 5.5 mmol/l Stop ACEi / ARB 100% increase in Cr or Cr >310 umol/l K+ >5.5 mmol/l McMurray J, Eur J Heart Fail 2005

MARKERS OF RISK - IS YOUR PATIENT DETERIORATING?

SEATTLE HEART FAILURE MODEL Derived from 1100 patients in the PRAISE trial NYHA III-IV, EF <30% Higher mortality: Na <138 mmol/l lower Hb lower lymphocytes lower cholesterol higher uric acid Renal function not predictive of outcome Levy WC, Circ 2006

MAGGIC SCORE 40,000 patients Creatinine the only blood test predictive of outcome Pocock SJ, Eur Heart J 2013

NATRIURETIC PEPTIDES (NP) BNP (<100pg/ml) / NT-proBNP (<300pg/ml) used as rule out test for acute HF 1,2 BNP (>400pg/ml) / NT-proBNP (>2000pg/ml) used to stratify patients for urgent assessment 3 NP elevated with many conditions - LVH, ischaemia, tachycardia, hypoxia, low GFR, sepsis, COPD, DM, age >70yrs, liver disease Diuretics, ACE, ARB, MRA, CRT reduce NP 4 BB may transiently increase NP for 2-3m before reducing 5 BNP elevated with sacubitril-valsartan and so use NT-proBNP in these patients 1 NICE CG 187, Acute Heart Failure, 2014 2 ESC Guidelines for HF, 2016 3 NICE CG 108, Chronic Heart Failure, 2010 4 Motiwala SR, Clin Pharm Ther 2013 5 Davis ME, Circ 2006

NP AS PROGNOSTIC MARKERS VAL-HEFT study 35% increase in risk for each 100pg/ml rise in BNP NT-proBNP O BNP NT-proBNP O BNP Deciles of NP Deciles of NP Masson S, Clin Chem 2006

NP GUIDED THERAPY Savarese G, PLoS ONE 2013

RENAL FUNCTION Cr >110umol/L associated with increased mortality in MAGGIC Rising urea also predicts mortality 1 Correlate with clinical assessment of fluid status and symptoms Relieving renal venous hypertension improves renal perfusion Beware of GI blood loss 2 Normal Cr-Ur ratio approx 10:1 In GI bleeding, Cr-Ur ratio <3:1 <5 mmol/l 7 mmol/l 14 mmol/l >16.5 mmol/l egfr may be more accurate than Cr Cr underestimates renal function in low muscle mass, elderly and women egfr less reliable in AKI 1 Novack V, PLoS ONE 2010 2 Witting MD, Am J Emerg Med 2006

HYPONATRAEMIA Sodium <136mmol in stable outpatients associated with risk of hospitalisation and death 1 Water excess or sodium depletion? Assess fluid status, paired urine/serum osmolality and urine sodium Measure Mg 2+, Ca 2+ and K + Beware of nephrotic syndrome, liver failure and hypothyroidism in oedematous patients Bailing L, Eur J Heart Fail 2011

HYPONATRAEMIA ASSESSMENT Longmore M, Oxford Handbook of Clinical Medicine, 7 th Ed, Oxford University Press 2007

LIVER FUNCTION TESTS Liver function tests comprise Bilirubin Alk Phos Gamma GT ALT Albumin Consider other causes of abnormal LFT Drugs (eg. ETOH, Abx, statins) Non-invasive liver screen USS liver cirrhosis, gallstones 14 Allen LA, Eur J Heart Fail 2009

HYPOALBUMINAEMIA Common in HF Causes Dilution? Inflammation Liver disease Renal loss (nephrotic syndrome) GI loss (protein losing enteropathy) Can consider replacing with iv Albumin if fluid overloaded Horwich TB, Am Heart J 2008

DIAGNOSING OTHER CONDITIONS

THYROID DISEASE Hypothalamus Hypothalamus Hypothalamus TRH TRH TRH Pituitary Gland Pituitary Gland Pituitary Gland TSH TSH TSH T3 / T4 Thyroid T3 / T4 Thyroid T3 / T4 Thyroid Normal Hypothyroid Hyperthyroid

IRON DEFICIENCY Very common in CHF and independent of anaemia Associated with higher NYHA class, hospitalisations and mortality iv iron improves exercise tolerance and reduces hospitalisations 1,2 1 Anker S, NEJM 2009 2 Ponikowski P, Eur Heart J 2014

IRON DEFICIENCY - BASICS Ferritin Ferritin

IRON DEFICIENCY HEART FAILURE Ferritin Ferritin

IRON DEFICIENCY - DIAGNOSIS Ferritin <100 ug/l Ferritin Fe Transferrin TSAT <20% (with Ferritin <300 ug/l) Microcytosis - MCV <80 fl

IRON DEFICIENCY - DIAGNOSIS Condition Serum Iron Transferrin / TIBC TSAT Iron deficiency Low High Low Anaemia of chronic disease Low Low Normal Oral contraceptives Normal High Low

SUMMARY Worsening NP, renal function, liver function, sodium and albumin may indicate deteriorating HF Correlate bloods with fluid status and symptoms Consider correcting iron deficiency with iv iron Consider alternative causes of abnormal bloods if it doesn t fit with the HF Hypothyroidism Liver disease Renal disease GI blood loss